A panel of experts discuss navigating access challenges in CLL treatment.
Video content above is prompted by the following question(s):
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
2 Commerce Drive
Cranbury, NJ 08512